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 Social competence scale and Behavior problem scale of 1217 years
old
Male
12-17
(N 38)
Mean  SD
Standard of
Male
Mean  SD
Female
12-17
(N 25)
Mean  SD
Standard of
Female
Mean  SD
< Social
competence
>
Socialization 5.63  2.08 5.48  1.39 6.09  1.80 5.55  1.29
Studying
competence 3.60  0.88 3.83  0.77 3.78  0.77 3.84  0.70
Total Social
competence 9.33  2.64 9.31  1.69 10.13  2.05 9.39  1.58
< Behavior
problems >
Withdrawan 2.92  2.47 2.51  2.60 3.48  3.15 2.81  2.86
Somatic
Complaints 3.42  3.46 2.11  2.35 2.56  2.70 2.64  2.73
Anxious /
Depressed 4.13  3.36 3.31  3.47 5.84  4.65 4.18  4.08
Social Problems 3.47  2.79 1.93  2.19 3.00  2.19 1.90  2.09
Thought
Problems 1.07  1.34 0.83  1.31 1.52  1.32 0.80  1.41
Attention
Problems 4.13  2.80 4.25  3.43 4.76  3.21 3.97  3.30
Delinquent
Behavior 0.97  1.07 1.64  2.10 1.36  1.43 1.20  1.94
Aggressive
Behavior 5.21  3.89 5.36  5.30 6.92  3.49 5.90  5.07
Internalizing
Problems 10.23  6.90 7.80  6.98 11.48  8.38 9.37  8.11
Externalizing
Problems 6.18  4.35 7.00  6.63 8.28  4.55 7.10  6.47
Total Behavior
Promblems 28.97  16.50 25.73  20.63 32.64  16.73 26.83  21.72
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FUNDAMENTAL NURSING RESPONSIBILITIES IN MESENCHYMAL STEM
CELL INFUSION
Maldonado, M.1, Kebriaei, P.1, Granada, M.L.A.1, Szewczyk, N.1
1MD Anderson Cancer Center, Houston, TX.
Prevention and treatment of graft versus host disease (GVHD)
continues to be a challenge in the ﬁeld of Stem Cell Transplanta-
tion and Cellular Therapy (SCTCT). It may take multidrug ther-
apy with different mechanisms to control GVHD. Mesenchymal
Stem Cell (MSC) infusion is a new form of cellular therapy, which
may be potentially efﬁcacious in the treatment of GVHD. MSC
have the unique capability of differentiating into various tissues,
and can help in the repair process necessary in GVHD. These are
cells obtained in the adult bone marrow that may assist to control
how the immune system responds to foreign substances and nur-
ture the growth of new blood cells in the bone marrow. Finally, it
has immunomodulatory effects that are essential in treating
GVHD.
SCTCT nurses play a vital role in managing the care of patients
with GVHD. It is imperative that they have a strong knowledge
base of the accountabilities that surround them when involved in
the care of a patient receiving MSC. Close monitoring for possible
toxicities and serious adverse effects pre-, during and post infu-
sions, and proper documentation of assessments and ﬁndings, are
important as well. Upon understanding such, this will aid them to
immediately identify complications and relay accurate ﬁndings to
the physicians. Patient teaching plays an enormous role in the
administration of MSC because a well- informed patient is able to
comprehend their treatment, therefore, being proactive with their
care.
The tool developed to assist SCTCT nurses to identify the
standard procedures, such as pre-printed orders, the nursing re-
sponsibilities pre, during and post transfusion of MSC and a case
study will be presented. Consideration to incorporate this infor-
mation into annual competency check is being discussed.
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THE ROLE OF IMMUNOGLOBULIN IN HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Martin, A.1, Neumann, J.1 1The University of Texas M.D. Anderson
Cancer Center, Houston, TX.
Topic/Purpose:
It is critical to be knowledgeable about the indications, mecha-
nisms of action (MOA), and administration of medications and
treatments delivered in order to educate patients, eliminate med-
ication errors, and watch for harmful side effects. Intravenous
Immunoglobulin (IVIg) is a complex drug administered frequently
by nurses to certain patients receiving a hematopoietic stem cell
transplant (HSCT) as a standard of care for infection prevention,
and for other, lesser-known uses. In conversations with staff nurses
and new graduate nurses, a serious need has been identiﬁed to
educate nurses about the indications, MOA, and administration of
IVIg to ensure patient safety and improve nursing knowledge.
Intervention:
A presentation will be offered to nurses working with HSCT
patients exploring the current uses and indications of IVIG, how it
works, precautions for administration, and investigational uses.
Discussion:
Infection is the number one complication in patients receiving a
HSCT. Approximately half of all the patients receiving unrelated
donor stem cells develop at least one major, life-threatening infec-
tion post-transplant. IVIg is an infusion frequently used in patients
to help prevent or reduce the occurrence of these infections.
Immunoglobulins are antibodies found in the blood serum that
play a key role in identifying and destroying harmful foreign bodies
or antigens. These antibodies are subject to myelosuppressive
agents such as high-dose chemotherapy or immunosuppressants
after transplantation. IVIg is given to these patients to replace and
supplement the immunoglobulin deﬁciency. Although there is
some controversy surrounding its use, studies have suggested that
regular supplementation in these patients help prevent major in-
fections.
There are multiple issues related to the administration of IVIg. It
is derived from human blood products, therefore patients are at
risk for reactions during infusion. Nurses must be aware of all
possible reactions and monitor the patients during administration.
Evaluation:
Intravenous Immunoglobulin competency for nursing staff and
post testing for effectiveness is being developed.
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MORE THAN MY MARROW: DEVELOPMENT AND IMPLEMENTATION OF
A HEMATOPOIETIC STEM CELL DONOR RECOGNITION PROGRAM
McMullin, B.1, Sorensen, S.1, Choroszy, M.1, Carstens, K.1 1M.D.An-
derson Cancer Center and Children’s Cancer Hospital, Houston, TX.
Although alternative stem cell sources have expanded the hema-
topoietic stem cell transplant (HSCT) repertoire, a signiﬁcant
number of HSCT recipients still receive stem cells from related
donors. Related donors are frequently minor or adult-aged sib-
lings, but parents, children and other relatives of recipients may be
called upon to donate. Most donors are altruistic, but nonetheless
feel tremendous pressure to donate and can experience distress. Up
to half of the donors may face difﬁculties, which include sleep
disturbances, behavior problems, and poor academic achievement.
Feelings of resentment and guilt are commonly expressed. Pre-
donation ambivalence, donor’s perception of the adequacy of in-
formation provided, donor’s participation in the decision to do-
nate, and the quality of donor-recipient relationship are four
variables that have been associated with donor distress. Services
provided to donors are variable and often only related to immedi-
ate procedural concerns with little post-donation follow-up. Given
the frequent and signiﬁcant related donor and potential donor
distress, prophylactic services should be implemented to assist
donors with not only the procedural and physical issues but also the
psychosocial issues. Approximately 300 related HSCT donors are
chosen annually at our institution. Such prophylactic service pro-
vision is currently absent for the adult-aged related donors, and is
limited for minor-aged related donors to the obtaining of assent
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and procedural coping skills. To minimize related donor distress, a
multidisciplinary team worked to develop a “Donor Recognition
Program” which includes acknowledgement, education, counsel-
ing, and support. All donors will receive a specially designed T-
shirt. Minor donors will undergo pre- and post-procedure coun-
seling, and will have a needs assessment at 2, 4, 6, and 12 months
post-donation to determine issues and facilitate adjustment related
to donation and recipient outcome. Baseline and 1 year post do-
nation measures of behavior, anxiety, and esteem for minor par-
ticipants will be compared to evaluate the program. For adults, a
donor questionnaire will be developed, tested, reﬁned and distrib-
uted to related donors at the time of donation, two weeks after
donation and two months after the patient is transplanted. The
results of this questionnaire will be used to evaluate the need for
creating additional adult donor services and/or to reﬁne practices
and processes at this institution.
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HEART SUCCESS WITH BLOOD & MARROW TRANSPLANT PATIENTS: A
MULTIDISCIPLINARY APPROACH FOR CONGESTIVE HEART FAILURE
PATIENTS
Meyers, A.L.1, Trueman, A.1, Johnston, P.1, Woods, M.1, Fadol, A.1,
Oliver, T.1, Martin, A.1 1MD Anderson Cancer Center, Houston, TX.
By 2010 it is estimated that the American population aged 65 and
older will increase to over 40 million individuals. This increase is
already evident in our Blood and Marrow transplant population
with an older population being transplanted with increased survival
rates post transplant. Increased age translates into co-morbid con-
ditions that contribute to a signiﬁcant proportion of morbidity and
mortality. One example of this includes cardiovascular conditions
that patients bring with them at an increasing rate as they advance
in age. The average rates of cardiovascular events rise from 7 per
1,000 men ages 35-44 to 68 per 1,000 men ages 85-94 with
narrowing gaps with advancing age and comparable rates occur 10
years later in life for women.
Congestive heart failure (CHF) is one of those cardiovascular
co-morbid conditions that this patient population continues to
bring into the transplant setting or is developed as a result of
treatment. CHF affects 1.5-2% of the population and increases
6-10% in people greater than 65 years of age. In 2005, more than
400 patients were hospitalized at the comprehensive cancer center
with a discharge diagnosis of CHF totaling a cost of 36 million
dollars. Cancer patients with heart failure can have improved
clinical outcomes.
To improve clinical outcomes of these patients, we have teamed
together with cardiology and have implemented a Heart Success
Program on the 52-bed inpatient unit. The program entails education
of the staff and patients about the symptoms of CHF, the importance
of daily weights, medications, walking, energy conservation, and nu-
trition. The program is a multidisciplinary approach including Phar-
macy, APN’s, Nursing, Rehabilitation services, Social Work, Case
Management, andNutrition. The goals for the staff utilizing the heart
success program include increasing the nurses’ awareness of the
pathophysiology and pharmacology of CHF, being more proactive in
its recognition, and identifying patients eligible for the program. The
overall goals are to have a reduction in hospital admissions for heart
failure exacerbation, decrease the length of stay and healthcare dollars
spent. Weekly rounds are conducted with Cardiology and the multi-
disciplinary team to review the CHF patients and their treatment. In
addition, a monthly meeting is held with Heart Success members to
look at the data from these patients to evaluate treatment outcomes. A
case will be presented.
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NURSING CARE OF THE CHILD RECEIVING INHALED RIBAVIRIN FOR
THE TREATMENT OF RSV IN THE PERITRANSPLANT PERIOD
Murphy, C.1, Frey, M.1, Kurtzberg, J.1 1Duke University Hospital,
Durham, NC; The Duke Pediatric Blood and Marrow Transplant
Program, Durham, NC.
Children status post blood and marrow transplantation have
poor immune function putting them at high risk for serious viral
infections of the respiratory tract. RSV, Parainﬂuenza and Ad-
enovirus can cause serious infections in these patients. First line
therapy generally includes IVIG and supportive care. Synagis
can be used to prevent RSV if the potential for exposure is
known in advance of the infection. Ribavirin is an antiviral agent
that can be used in the post BMT patient who contracts RSV.
There is some data to suggest Ribavirin also has activity against
Parainﬂuenza types 1, 2 and 3, and Adenovirus. The criteria for
administration of inhaled Ribavirin are persistent infection de-
spite appropriate treatment and if there is evidence of lower
respiratory infection manifested by pulmonary inﬁltrates, oxy-
gen requirements or respiratory distress. Special precautions
must be taken when caring for a child receiving Ribavirin via
inhalation. Of special concern is the risk of exposure to the
family and caregiver. Inhaled Ribavirin is often poorly tolerated
and the administration of this therapy requires careful planning.
The purpose of this abstract is to describe the indications and
side effects of inhaled Ribavirin. The nursing care associated
with patients receiving inhaled Ribavirin will also be presented.
Speciﬁc goals will be to describe the administration techniques
and safety precautions that must be taken by caregivers and staff.
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USE OF N-ACETYLCYSTEINE FOR HEPATIC VENO-OCCLUSIVE DISEASE
PROPHYLAXIS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANS-
PLANT PATIENTS
Englert, L.1, Murphy, P.1, Quinn, M.1, Tat, C.1 1UCSF Children’s
Hospital, San Francisco, CA.
Background: Veno-occlusive disease (VOD) of the liver is one
of the early complications following hematopoietic stem cell trans-
plantation (HSCT) due to liver damage caused by pre-transplant
chemotherapy and/or total body radiation. The incidence of VOD
in the pediatric HSCT population is approximately 25% with 80%
of those having mild to moderate disease only requiring supportive
measures and 20% developing severe disease. The mortality rate is
as high as 50% for those who develop severe VOD. In a study
conducted at UCSF Children’s Hospital from March 2002
through June 2005, 12% of patients who received myeloablative
conditioning regimens developed VOD. Of those, 62% had mild/
moderate disease, 38% had severe, and 3% died from VOD. The
Pediatric Bone Marrow Transplant (PBMT) Program at UCSF
Children’s Hospital has experience using ﬁbrinolytic agents and/or
an anticoagulant for treatment of severe VOD to target the clot-
ting phenomenon. However, prophylaxis for VOD is still ques-
tionable and not well studied. N-Acetylcysteine (NAC) is currently
approved for use as a mucolytic agent in certain pulmonary disor-
ders and as an antidote for acetaminophen overdose. Evidence thus
far has shown its potential beneﬁts in preventing VOD in patients
undergoing HSCT without affecting the desired effects of condi-
tioning regimens.
Methods: Using the group from our initial study of VOD as our
control, we conducted a retrospective review of 17 patients who
received NAC between 2005-2006. Both groups were treated with
similar myeloablative conditioning regimens. We compared the
incidence of VOD in the two groups. For the NAC group, NAC
100 mg/kg/dose was given IV over 2 hours on day of admission,
Day 1 and Day 2 post-transplant (a fourth dose was given to
patients who received Busulfan/Cyclophosphamide combination
therapy).
Results: Results to be presented at the 2007 BMT Tandem
Meetings.
Conclusion: The use of NAC in the pediatric HSCT population
is a novel approach to preventing severe VOD, but requires pro-
spective studies to be conducted. Administration of NAC during
the pre and post transplant period increases nurse education and
awareness to the risks of VOD and gives them the opportunity to
participate in research that may improve their patients’ transplant
outcomes.
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